Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Therapeutic Solutions International Inc TSOI

Therapeutic Solutions International, Inc. is focused on immune modulation for the treatment of several specific diseases. The Company is developing a range of immune-modulatory agents to target certain cancers, schizophrenia, suicidal ideation, and traumatic brain injury (TBI), and for daily health. Its flagship product, QuadraMune, is a multi-patented synergistic blend of pterostilbene... see more

Recent & Breaking News (OTCPK:TSOI)

Therapeutic Solutions International Identifies New Mechanism of Mesenchymal Stem Cell Treatment of Brain Injury

PR Newswire October 27, 2020

Therapeutic Solutions International Reports Positive Preclinical Data on Multiple Sclerosis using NanoStilbene(TM)

PR Newswire October 19, 2020

Therapeutic Solutions International Appoints Serena Robella as Director of Sales

PR Newswire October 12, 2020

Therapeutic Solutions International announced today appointment of J Christopher Mizer to the Advisory Board of its Campbell Neurosciences Division

PR Newswire October 5, 2020

Therapeutic Solutions International Reports Positive Preclinical Data on JadiCell(TM) Universal Donor Stem Cell Therapy for Brain Injury

PR Newswire September 28, 2020

Therapeutic Solutions International Announces Proof of Concept Data and Patent Filing for Neuroleukin(TM): The First Immune Based Suicide Prevention Biological Therapy

PR Newswire September 24, 2020

Therapeutic Solutions International Files Comprehensive Campbell Platform(TM) Patent for Stem Cell Immunotherapy of Schizophrenia

PR Newswire September 14, 2020

Therapeutic Solutions International Reports Synergistic Suppression of Suicide-Associated Neuroinflammatory Pathway by QuadraMune(TM) and Minocycline

PR Newswire August 28, 2020

Therapeutic Solutions International Files Patent on Campbell Score(TM): The First Quantitative Tool for Assessment of Suicidal Propensity based on Immunological Markers

PR Newswire August 21, 2020

Therapeutic Solutions International Launches Campbell Neurosciences Division aimed at Biologically Identifying and Repairing Suicide-Prone Brains

PR Newswire August 11, 2020

Therapeutic Solutions International Reports Reduction of Inflammation Associated Memory Impairment by QuadraMune(TM) Administration

PR Newswire August 5, 2020

Therapeutic Solutions International Files Patent on Ability of QuadraMune Ingredient Pterostilbene to Reduce Inflammation while Stimulating Brain Protective Biological Pathways

PR Newswire July 28, 2020

Therapeutic Solutions International Reports Unexpected Findings of Synergy between QuadraMune(TM) and Diabetes Drug Metformin in Animal Models of COVID-19 Lung Damage

PR Newswire July 22, 2020

Therapeutic Solutions International Reports QuadraMune(TM) Inhibits Inflammation Induced Blood Clotting: Possible Implication for Ongoing Covid-19 Prevention Clinical Trial?

PR Newswire July 13, 2020

Therapeutic Solutions International Submits Publication on StemVacs(TM) Preclinical Data Supporting COVID-19 Indication

PR Newswire July 7, 2020

Therapeutic Solutions International Universal Donor Immunotherapy StemVacs(TM) Activates Antiviral Immune Cells While Protecting Lungs From "Cytokine Storm"

PR Newswire June 30, 2020

Therapeutic Solutions International Announces Intention to Use Clinical Stage NK Activating Cancer Immunotherapy for COVID-19

PR Newswire June 22, 2020

Therapeutic Solutions International Reports Reduction of Brain Inflammation/Depression Associated Biochemical Pathway Using QuadraMune(TM) in Animal Studies

PR Newswire June 15, 2020

Therapeutic Solutions International Issues "NOT US" Notice to Shareholders

PR Newswire June 15, 2020

Therapeutic Solutions International Reports QuadraMune Reduces Myeloid Suppressor Cells in 4T1 Mouse Model of Breast Cancer

PR Newswire June 11, 2020